Nitrofurantoin: Nursing Drug Guide, Pulmonary Toxicity & Renal Hold Rules
Nitrofurantoin is a bladder-focused antibiotic—not a substitute for upper-tract or systemic infection therapy. Before every dose, confirm acute uncomplicated cystitis (not pyelonephritis), verify creatinine clearance is at least 60 mL/min, give Macrobid with food, and stop therapy at the first sign of new cough, fever, dyspnea, or pulmonary infiltrates.
Acute, subacute, and chronic pulmonary reactions have occurred with nitrofurantoin—including fatalities. If cough, dyspnea, chest pain, fever, or infiltrates develop, discontinue nitrofurantoin and escalate per facility protocol. Nitrofurantoin is contraindicated when creatinine clearance is below 60 mL/min, with anuria or oliguria, or clinically significant elevated serum creatinine—impaired excretion increases toxicity risk. It is indicated only for acute uncomplicated urinary tract infection (acute cystitis) and is not indicated for pyelonephritis or perinephric abscess because it lacks adequate tissue distribution. Do not treat flank pain, high fever, or systemic illness with nitrofurantoin alone.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Hold nitrofurantoin when creatinine clearance is below 60 mL/min, when the patient has flank pain or systemic signs suggesting pyelonephritis, or when new cough, fever, dyspnea, or chest pain appears during therapy. Give Macrobid with food, complete the 7-day course only when the indication and renal function are appropriate, and question any order that uses nitrofurantoin for upper-tract or bloodstream infection.
Most common brand names
Macrobid (nitrofurantoin monohydrate and macrocrystals) is the dual-release capsule most often used for acute uncomplicated cystitis: 100 mg per capsule (25 mg macrocrystals plus 75 mg monohydrate). Macrodantin (nitrofurantoin macrocrystals) is a different formulation with different dosing (often 50–100 mg every 6 hours)—do not interchange products on the MAR without pharmacy verification.
Generic nitrofurantoin capsules and oral suspension may also appear. Confirm product name, strength, and whether the order matches Macrobid (100 mg every 12 hours) versus macrocrystal-only regimens.
Why we give it — Indications
Macrobid is indicated only for treatment of acute uncomplicated urinary tract infections (acute cystitis) caused by susceptible strains of Escherichia coli or Staphylococcus saprophyticus per FDA-approved labeling. Nurses see it for outpatient and inpatient urinary tract infection when symptoms are limited to lower-tract dysuria, frequency, and urgency without systemic illness.
Nitrofurantoin is not indicated for pyelonephritis or perinephric abscesses because it lacks the broader tissue distribution of agents used for upper-tract infection. Patients with dysuria with fever, flank pain, rigors, nausea with vomiting, or other systemic signs need prescriber review—nitrofurantoin alone is the wrong tool for pyelonephritis.
| Use | Detail |
|---|---|
| Acute uncomplicated cystitis | Susceptible E. coli or S. saprophyticus; obtain urine culture when ordered before and after therapy per labeling |
| Not indicated | Pyelonephritis, perinephric abscess, prostatitis, bloodstream infection, or other non–lower-urinary-tract infections |
| Antimicrobial stewardship | Use only for proven or strongly suspected bacterial infection to limit resistance per labeling |
On a small screen, swipe or scroll sideways to see the full table.
If bacteriuria persists or recurs after nitrofurantoin, agents with broader tissue distribution should be selected per prescribing information—not another blind course of nitrofurantoin for upper-tract disease.
How it works
Nitrofurantoin is bactericidal in urine at therapeutic concentrations. Bacterial flavoproteins reduce nitrofurantoin to reactive intermediates that inactivate ribosomal proteins and other macromolecules, disrupting protein synthesis, aerobic energy metabolism, DNA synthesis, and cell wall synthesis. Because the drug concentrates in urine with low plasma levels, it treats bladder-level infection but does not reliably treat renal parenchyma or systemic infection—explaining why pyelonephritis is out of scope.
Resistance development has been uncommon since introduction, but nitrofurantoin is not active against most Proteus or Serratia and has no activity against Pseudomonas per labeling. Antagonism with quinolone antimicrobials has been demonstrated in vitro; clinical significance is unknown.
Dosing overview
Macrobid capsules should be taken with food (ideally breakfast and dinner) to improve tolerance and increase bioavailability by approximately 40% per labeling.
Adults and pediatric patients over 12 years: One 100 mg capsule every 12 hours for seven days for acute uncomplicated UTI.
Missed dose: Not specified in the reviewed Macrobid prescribing information. Do not double doses; contact prescriber or pharmacist for interval guidance.
Duration: Standard labeled course is 7 days for Macrobid in acute cystitis. Longer or repeated courses increase risk of chronic pulmonary and neuropathy reactions per warnings.
Onset, peak, duration, and half-life
| Parameter | Value | Nursing relevance |
|---|---|---|
| Plasma levels | Peak usually <1 mcg/mL after 100 mg Macrobid | Low systemic exposure—poor choice when infection is beyond the bladder |
| Urinary excretion | ~20–25% of dose recovered unchanged in urine over 24 h | Requires adequate renal function to excrete drug safely—review eGFR and creatinine clearance before therapy |
| Urine appearance | May impart brown color to urine | Teach expected harmless discoloration vs gross hematuria or infection signs |
| Food effect | Bioavailability ↑ ~40% with food | Schedule with meals; missed food may reduce efficacy and tolerance |
| Renal impairment | Contraindicated CrCl <60 mL/min | Accumulation increases pulmonary, hepatic, and neuropathy risk—hold and clarify MAR |
On a small screen, swipe or scroll sideways to see the full table.
Before you give it — Safety check
Pretreatment checks
- Confirm indication is acute uncomplicated cystitis—not pyelonephritis, urosepsis, or systemic infection
- Review serum creatinine and calculated creatinine clearance; hold if CrCl <60 mL/min or clinically significant elevated creatinine per contraindications
- Complete medication reconciliation for probenecid, sulfinpyrazone, and magnesium trisilicate antacids
- Allergy history: prior nitrofurantoin reaction or cholestatic jaundice/hepatic dysfunction associated with nitrofurantoin
- Pregnancy status: contraindicated at term (38–42 weeks), during labor and delivery, or when labor is imminent; contraindicated in neonates under one month
- Verify MAR product (Macrobid vs Macrodantin vs generic) and 100 mg every 12 hours × 7 days schedule
Contraindications
- Anuria, oliguria, or significant renal impairment (creatinine clearance under 60 mL/min or clinically significant elevated serum creatinine)
- Known hypersensitivity to nitrofurantoin
- Previous cholestatic jaundice/hepatic dysfunction associated with nitrofurantoin
- Pregnancy at term, labor and delivery, or imminent labor; neonates under one month (hemolytic anemia risk)
- Macrobid contraindicated in infants below one month; safety not established in pediatric patients below 12 years
Important interactions
| Drug / factor | Effect | Nursing action |
|---|---|---|
| Magnesium trisilicate antacids | Reduced rate and extent of nitrofurantoin absorption | Do not administer concurrently; counsel patient per labeling |
| Probenecid / sulfinpyrazone | ↓ urinary excretion; ↑ serum levels and toxicity risk; ↓ urinary antibacterial efficacy | Alert pharmacist if uricosuric on profile |
| Urine glucose tests | False-positive glucose with Benedict’s or Fehling’s solution | Use enzymatic glucose tests when clinically relevant |
| Quinolone antibacterials | In vitro antagonism reported | Question duplicate UTI coverage; follow stewardship and pharmacy guidance |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Route: Oral Macrobid 100 mg capsule. Take with food to improve absorption and tolerance per labeling.
- Follow medication administration rights; verify patient, drug, dose, route, time, and allergy status
- Give with breakfast and dinner when possible per patient counseling in labeling
- Avoid magnesium trisilicate antacids during therapy
- Document exact times to maintain every-12-hour intervals for the 7-day course
- Encourage adequate fluids to promote urinary excretion unless fluid restriction is ordered
Expected therapeutic response
- Decreasing dysuria, frequency, and urgency within 48–72 hours for uncomplicated cystitis
- Defervescence when low-grade fever was present from lower-tract infection—persistent or rising fever suggests wrong drug or wrong site of infection
- Stable vital signs without new respiratory symptoms
- Post-therapy urine culture negative when ordered per labeling
Flank pain, rigors, or worsening systemic signs during therapy suggest pyelonephritis or complicated infection—notify prescriber; nitrofurantoin is not adequate monotherapy.
Red flags — Stop and act
Discontinue nitrofurantoin and escalate when pulmonary, hepatic, neurologic, or wrong-indication signals appear.
- New or worsening cough, shortness of breath, chest pain, fever, chills, or pulmonary infiltrates—possible acute, subacute, or chronic pulmonary hypersensitivity (can occur within the first week or after months of therapy)
- Flank pain, costovertebral tenderness, high fever, or rigors suggesting pyelonephritis—wrong indication for nitrofurantoin
- Creatinine clearance below 60 mL/min or rising creatinine during therapy
- Jaundice, dark urine, severe right upper quadrant pain, or marked transaminase elevation—possible hepatotoxicity
- Numbness, tingling, or burning in hands or feet—peripheral neuropathy may become irreversible if drug is continued
- Watery or bloody diarrhea with abdominal pain—evaluate for C. difficile-associated diarrhea
- Systemic allergic reaction, angioedema, or severe rash
- Anemia, pallor, or hemoglobinuria—evaluate for hemolytic anemia (especially G6PD deficiency)
Adverse effects
| Adverse effect | Frequency / context | Nursing response |
|---|---|---|
| Nausea, headache, flatulence | Most frequent in Macrobid trials (~8% nausea, ~6% headache) | Give with food; hold and escalate if severe or accompanied by pulmonary/hepatic signs |
| Pulmonary reactions | Acute (often first week), subacute, or chronic (often ≥6 months); fatalities reported | Discontinue nitrofurantoin immediately; notify prescriber; monitor oxygenation and respiratory status |
| Hepatotoxicity | Hepatitis, cholestatic jaundice, chronic active hepatitis—fatalities reported | Stop drug; monitor LFTs per prescriber; never rechallenge after cholestatic reaction |
| Peripheral neuropathy | May be severe or irreversible; risk ↑ with renal impairment, diabetes, anemia, vitamin B deficiency | Stop at first sensory symptoms; document and notify prescriber |
| Hemolytic anemia | Primaquine-sensitivity type; linked to G6PD deficiency | Discontinue; evaluate hemolysis per labeling |
| C. difficile-associated diarrhea | Reported with nearly all antibacterials including nitrofurantoin | Hold antibiotic; infection-control and stool work-up per protocol |
On a small screen, swipe or scroll sideways to see the full table.
Overdose and toxicity
Occasional acute overdoses have not produced specific symptoms other than vomiting per labeling. Induction of emesis is recommended. Maintain high fluid intake to promote urinary excretion. Nitrofurantoin is dialyzable. There is no specific antidote in the reviewed prescribing information.
Contact your facility’s poison control or medical toxicology service per local protocol for large ingestions, protracted vomiting, or uncertainty about total dose taken.
Look-alike / sound-alike and error prevention
- Macrobid vs Macrodantin—both nitrofurantoin but different release forms and dosing (100 mg q12h vs 50–100 mg q6h)
- Nitrofurantoin vs nitroglycerin / other “nitro” drugs—verify generic name on every pass
- UTI antibiotic confusion—do not substitute cephalexin or fluoroquinolones without prescriber order; each has different indication and renal rules
- Pyelonephritis treated as cystitis—flank pain and high fever mean nitrofurantoin is the wrong order
- Standard dose with CrCl 45–59—common renal error; CrCl <60 is contraindicated, not a dose-adjustment scenario
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Food | Pair doses with meals—empty-stomach doses may reduce absorption and increase nausea |
| Brown urine | Expected discoloration from nitrofurantoin; teach difference from gross hematuria |
| CrCl trap | Elderly patients often have CrCl 45–55—still contraindicated; do not give “because it is just a bladder drug” |
| Pulmonary watch | Ask about cough and exertional dyspnea at every visit—even early in a 7-day course |
| Wrong indication | Costovertebral angle tenderness or rigors → pyelonephritis pathway, not another nitrofurantoin course |
| Ask pharmacy when | Unclear CrCl, probenecid on profile, pregnancy at term, prior nitrofurantoin jaundice, or recurrent UTI after completed course |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Renal impairment (CrCl <60) | Contraindicated—increased pulmonary, hepatic, and neuropathy toxicity from impaired excretion |
| Elderly patients | Higher proportion of pulmonary reactions (including fatalities) reported with long-term therapy; greater likelihood of decreased renal function—monitor renal function |
| Acute kidney injury | Hold nitrofurantoin; recalculate clearance before any dose |
| Diabetes, anemia, vitamin B deficiency, debility | Increased peripheral neuropathy risk per labeling |
| G6PD deficiency | Hemolytic anemia risk—more common in populations noted in labeling |
| Pregnancy at term / labor | Contraindicated—hemolytic anemia risk in neonates |
| Infants <1 month / children <12 years | Contraindicated or safety not established for Macrobid per labeling |
| Long-term or prophylactic use | Chronic pulmonary reactions more common after ≥6 months—requires pulmonary monitoring per warnings |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Renal function and creatinine clearance before and during therapy in older adults or when AKI is possible
- Respiratory status: cough, dyspnea on exertion, oxygen saturation, and chest imaging when pulmonary reaction is suspected
- Lower-tract symptom resolution vs flank pain or systemic signs
- Urinalysis and culture results when ordered before and after therapy per labeling
- Urinary output measurement when patient is acutely ill or receiving other nephrotoxic therapy
- GI tolerance, hepatic symptoms, and neurologic complaints (numbness, tingling)
- Hemoglobin if anemia or hemolysis is suspected
Document
- Indication documented as acute uncomplicated cystitis—not pyelonephritis
- CrCl or eGFR value supporting therapy; pharmacy clarification when borderline
- Doses given with food and completion of 7-day course
- Any pulmonary, hepatic, or neuropathic symptom with onset time and prescriber notification
Patient teaching
- Take every dose with food for the full 7 days unless the prescriber stops early
- Urine may turn brown—this is expected; report painful urination that worsens, flank pain, or fever returning
- Report cough, shortness of breath, chest pain, fever, or chills immediately—do not take another dose first
- Report numbness, tingling, or burning in hands or feet
- Do not use magnesium trisilicate antacids during therapy
- Report watery or bloody diarrhea, severe abdominal pain, or jaundice
- This antibiotic treats bladder infection only—if you develop back/flank pain or high fever, seek care promptly
The Hold Rule
- Creatinine clearance below 60 mL/min, anuria, oliguria, or clinically significant elevated serum creatinine
- New cough, dyspnea, chest pain, fever with pulmonary symptoms, or suspected pulmonary infiltrate during or after therapy
- Signs suggesting pyelonephritis (flank pain, CVA tenderness, high fever, rigors) or systemic urosepsis—wrong indication
- Known hypersensitivity or prior cholestatic jaundice/hepatic dysfunction with nitrofurantoin
- Peripheral neuropathy symptoms, significant hepatitis, hemolytic anemia, or serious allergic reaction
- Pregnancy at term, active labor, or neonate under one month
- Watery or bloody diarrhea pending C. difficile evaluation
Macrobid labeling contraindicates creatinine clearance below 60 mL/min, but renal cutoffs can differ by institutional policy and modern geriatric prescribing guidance—they are not always identical to the package insert. Confirm pharmacy and facility rules before borderline doses; follow prescriber orders and local protocol.
Clinical practice integration and workflow
Nitrofurantoin is effective for susceptible uncomplicated cystitis when renal function and indication are correct—and harmful when nurses treat it as a universal UTI drug. Build pulmonary screening and CrCl verification into every administration pass.
1. Check-before-you-give protocol
- Right patient, drug, dose (100 mg), route, time—and Macrobid vs Macrodantin product match
- Indication = acute uncomplicated cystitis without pyelonephritis signs
- Creatinine clearance at least 60 mL/min documented or pharmacy-cleared
- Dose scheduled with food; antacids reviewed
2. High-alert and safety badge
Not on standard high-alert list — pulmonary, renal, and indication errors still high-stakesFatal pulmonary reactions and contraindicated use in CrCl <60 require the same vigilance as many high-alert workflows even when the product lacks a universal high-alert designation.
3. Clinical workflow: hold and question rules
- Question nitrofurantoin for flank pain, rigors, or orders labeled “pyelonephritis” or “complicated UTI”
- Hold when CrCl <60 appears on labs without prescriber acknowledgment
- Stop and escalate at first pulmonary symptom—do not finish the 7-day course first
4. Critical teach-back questions
- “What symptoms mean you should stop and call right away?” (Cough, shortness of breath, chest pain, flank pain, high fever, numbness or tingling.)
- “How should you take this antibiotic?” (With food, every 12 hours, complete 7 days unless told to stop for side effects.)
5. Care coordination
Pharmacist: CrCl verification, Macrobid vs Macrodantin clarification, probenecid interaction, alternative antibiotic when pyelonephritis or CrCl <60 is present.
Prescriber: Notify for pulmonary symptoms, persistent bacteriuria, pyelonephritis signs, hepatotoxicity, neuropathy, or need for broader-spectrum therapy.
🧠 Quick mental checklist
- Is this truly uncomplicated cystitis—not pyelonephritis or systemic infection?
- Is creatinine clearance at least 60 mL/min?
- Any new cough, fever, dyspnea, or chest pain since the last dose?
- Is Macrobid 100 mg q12h with food on the MAR—not Macrodantin dosing?
- Flank pain or rigors developing during therapy?
Nitrofurantoin NCLEX practice questions
Practice NCLEX-style clinical judgment practice for nitrofurantoin with a tabbed case (MAR, labs, vitals, nursing notes), then priority action, cue recognition (SATA), trend interpretation, matrix urgency matching, indication judgment, and documentation cloze—recognise pulmonary toxicity and renal hold cues → analyse → prioritise → act → evaluate outcomes.
Select a tab to view MAR, labs, vitals, and nursing note details for this case.
- Nitrofurantoin (Macrobid) 100 mg PO q12h with meals — 0800 and 2000 given; 2000 dose due tonight
- Acetaminophen 650 mg PO q6h PRN — one dose for flank discomfort at 1400
- Prescriber diagnosis on chart: “UTI” — antibiotic started on admission
- Pharmacy note (yesterday): “CrCl 48 — verify indication” (no hold entered)
- Creatinine 1.6 mg/dL (baseline 1.4); creatinine clearance 48 mL/min
- Urinalysis: positive nitrites, WBC esterase, many bacteria; no casts
- WBC 12.4 ×10⁹/L; C-reactive protein elevated
- Chest X-ray (today): new bilateral infiltrates per radiology preliminary read
- Temp 38.6 °C (was 37.2 °C this morning)
- BP 102/64, HR 104, RR 24, SpO2 93% on room air
- Reports chills and productive cough since noon
- 78-year-old female admitted for dysuria; day 3 of Macrobid
- Now reports right costovertebral angle tenderness and nausea; denies vomiting
- Student nurse states, “Macrobid treats kidney infection because it is a UTI antibiotic”
- Attending progress note (admission): “likely cystitis” — no updated assessment after flank pain began
Answer key & rationale
Frequently asked questions
Why is pulmonary toxicity the primary nursing concern with nitrofurantoin?
Prescribing information warns that acute, subacute, and chronic pulmonary reactions have occurred with nitrofurantoin—including reports contributing to death. Acute reactions often present with fever, chills, cough, chest pain, dyspnea, and infiltrates, frequently within the first week. Chronic reactions may develop insidiously after six months or longer. Nurses must stop the drug and escalate when new respiratory symptoms appear.
When must a nurse hold nitrofurantoin for renal function?
Nitrofurantoin is contraindicated with anuria, oliguria, or significant renal impairment defined as creatinine clearance under 60 mL/min or clinically significant elevated serum creatinine per Macrobid labeling. Impaired excretion increases pulmonary, hepatic, and neuropathy risk. There is no labeled dose reduction—do not give standard therapy when clearance is below the contraindication threshold. Renal cutoffs may differ by institutional policy and geriatric prescribing guidance; confirm pharmacy and facility rules when CrCl is borderline before any dose.
Can nitrofurantoin treat pyelonephritis or kidney infection?
No. Labeling states nitrofurantoin is not indicated for pyelonephritis or perinephric abscesses because it lacks adequate tissue distribution compared with agents used for upper-tract infection. Flank pain, high fever, and CVA tenderness require different therapy—question orders that use Macrobid alone for these findings.
What is the correct Macrobid dose and how should patients take it?
Adults and patients over 12 years: one 100 mg capsule every 12 hours for seven days. Capsules should be taken with food (ideally breakfast and dinner) to improve tolerance and absorption. Complete the course unless a serious adverse reaction occurs.
What adverse effects should nurses monitor besides pulmonary reactions?
Also monitor for hepatotoxicity (jaundice, hepatitis), peripheral neuropathy (numbness or tingling), hemolytic anemia in G6PD deficiency, hypersensitivity, and C. difficile-associated diarrhea. Common effects include nausea, headache, and brown urine discoloration.
Is nitrofurantoin safe in pregnancy and breastfeeding?
It is contraindicated at term (38–42 weeks), during labor and delivery, or when labor is imminent, and in neonates under one month because of hemolytic anemia risk. Nitrofurantoin is detected in breast milk in trace amounts—decisions should weigh maternal need against potential infant effects per labeling. Use during earlier pregnancy only if clearly needed.
References
-
U.S. National Library of Medicine. Macrobid (nitrofurantoin monohydrate and macrocrystals) — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1971e893-5fdb-41e3-a1e9-5e52deed03d1
-
U.S. National Library of Medicine. Macrodantin (nitrofurantoin macrocrystals) — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ec86b651-d77d-4a42-b493-24244456b3f6
-
Drugs and Lactation Database (LactMed). Nitrofurantoin. Bethesda (MD): National Institute of Child Health and Human Development.https://www.ncbi.nlm.nih.gov/books/NBK501053/
-
National Institute for Health and Care Excellence. Nitrofurantoin. BNF.https://bnf.nice.org.uk/drugs/nitrofurantoin/
-
U.S. Food and Drug Administration. MedWatch: The FDA Safety Information and Adverse Event Reporting Program.https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.